Percutaneous approaches for efficient cardiac gene delivery

Journal of Cardiovascular Translational Research

Volumn 6, Issue 4, 2013, Pages 649-659

  Ishikawa, Kiyotake ^a   Aguero, Jaume ^a   Naim, Charbel ^a   Fish, Kenneth ^a   Hajjar, Roger J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Distribution; Endovascular; Gene delivery; Injection; Pericardial

Indexed keywords

ADENOVIRUS VECTOR; CARDIOVASCULAR AGENT; FIBROBLAST GROWTH FACTOR 4; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOSOME; MYC PROTEIN; PARVOVIRUS VECTOR; PLASMID DNA; PLASMID VECTOR; POLYMER; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN C; VIRUS VECTOR; VM 202;

ARTERY CATHETERIZATION; ARTICLE; BALLOON CATHETER; CARDIOVASCULAR GENE THERAPY; COMPARATIVE EFFECTIVENESS; DOSE RESPONSE; DRUG MEGADOSE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HEART MUSCLE; HEART MUSCLE PERFUSION; HUMAN; ISCHEMIC CARDIOMYOPATHY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERFUSION PRESSURE; PRIORITY JOURNAL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEART FAILURE; HUMANS; INJECTIONS; MYOCARDIUM; TRANSDUCTION, GENETIC; TREATMENT OUTCOME;

EID: 84880429682     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-013-9479-7     Document Type: Article

References (92)

1. Amado, L. C.; Saliaris, A. P.; Schuleri, K. H.; St John, M.; Xie, J. S.; Cattaneo, S.; et al. (2005). Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A, 102, 11474-11479.
2. Asokan, A. (2010). Reengineered AAV vectors: old dog, new tricks. Discov Med, 9, 399-403.
3. Asokan, A.; Conway, J. C.; Phillips, J. L.; Li, C.; Hegge, J.; Sinnott, R.; et al. (2010). Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol, 28, 79-82.
4. Baklanov, D. V.; de Muinck, E. D.; Simons, M.; Moodie, K. L.; Arbuckle, B. E.; Thompson, C. A.; et al. (2005). Live 3D echo guidance of catheter-based endomyocardial injection. Catheter Cardiovasc Interv, 65, 340-345.
5. Bish, L. T.; Sleeper, M. M.; Brainard, B.; Cole, S.; Russell, N.; Withnall, E.; et al. (2008). Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines. Mol Ther, 16, 1953-1959.
6. Boekstegers, P.; & Kupatt, C. (2004). Current concepts and applications of coronary venous retroinfusion. Basic Res Cardiol, 99, 373-381.
7. Boekstegers, P.; von Degenfeld, G.; Giehrl, W.; Heinrich, D.; Hullin, R.; Kupatt, C.; et al. (2000). Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther, 7, 232-240.
8. Bridges, C. R. (2009). 'Recirculating cardiac delivery' method of gene delivery should be called 'non-recirculating' method. Gene Ther, 16, 939-940.
9. Bridges, C. R.; Burkman, J. M.; Malekan, R.; Konig, S. M.; Chen, H.; Yarnall, C. B.; et al. (2002). Global cardiac-specific transgene expression using cardiopulmonary bypass with cardiac isolation. Ann Thorac Surg, 73, 1939-1946.
10. Bridges, C. R.; Gopal, K.; Holt, D. E.; Yarnall, C.; Cole, S.; Anderson, R. B.; et al. (2005). Efficient myocyte gene delivery with complete cardiac surgical isolation in situ. J Thorac Cardiovasc Surg, 130, 1364.
11. Brito, L. A.; Chandrasekhar, S.; Little, S. R.; & Amiji, M. M. (2010). Non-viral eNOS gene delivery and transfection with stents for the treatment of restenosis. Biomed Eng Online, 9, 56.
12. Byrne, M. J.; Power, J. M.; Preovolos, A.; Mariani, J. A.; Hajjar, R. J.; & Kaye, D. M. (2008). Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther, 15, 1550-1557.
13. Dangas, G. D.; Claessen, B. E.; Caixeta, A.; Sanidas, E. A.; Mintz, G. S.; & Mehran, R. (2010). In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol, 56, 1897-1907.
14. de la Fuente, L. M.; Stertzer, S. H.; Argentieri, J.; Penaloza, E.; Miano, J.; Koziner, B.; et al. (2007). Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow-up in an open-label, nonrandomized, single-center pilot study (the TABMMI study). Am Heart J, 154(79), e71-e77.
15. Di Pasquale, E.; Latronico, M. V.; Jotti, G. S.; & Condorelli, G. (2012). Lentiviral vectors and cardiovascular diseases: a genetic tool for manipulating cardiomyocyte differentiation and function. Gene Ther, 19, 642-648.
16. Donahue, J. K.; Kikkawa, K.; Johns, D. C.; Marban, E.; & Lawrence, J. H. (1997). Ultrarapid, highly efficient viral gene transfer to the heart. Proc Natl Acad Sci U S A, 94, 4664-4668.
17. Emani, S. M.; Shah, A. S.; Bowman, M. K.; Emani, S.; Wilson, K.; Glower, D. D.; et al. (2003). Catheter-based intracoronary myocardial adenoviral gene delivery: importance of intraluminal seal and infusion flow rate. Mol Ther, 8, 306-313.
18. Flugelman, M. Y.; Jaklitsch, M. T.; Newman, K. D.; Casscells, W.; Bratthauer, G. L.; & Dichek, D. A. (1992). Low level in vivo gene transfer into the arterial wall through a perforated balloon catheter. Circulation, 85, 1110-1117.
19. Fortuin, F. D.; Vale, P.; Losordo, D. W.; Symes, J.; DeLaria, G. A.; Tyner, J. J.; et al. (2003). One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am J Cardiol, 92, 436-439.
20. French, B. A.; Mazur, W.; Geske, R. S.; & Bolli, R. (1994). Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation, 90, 2414-2424.
21. Fromes, Y.; Salmon, A.; Wang, X.; Collin, H.; Rouche, A.; Hagege, A.; et al. (1999). Gene delivery to the myocardium by intrapericardial injection. Gene Ther, 6, 683-688.
22. Fuchs, S.; Dib, N.; Cohen, B. M.; Okubagzi, P.; Diethrich, E. B.; Campbell, A.; et al. (2006). A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease. Catheter Cardiovasc Interv, 68, 372-378.
23. Goldman, B.; Blanke, H.; & Wolinsky, H. (1987). Influence of pressure on permeability of normal and diseased muscular arteries to horseradish peroxidase. A new catheter approach. Atherosclerosis, 65, 215-225.
24. Grines, C. L.; Watkins, M. W.; Helmer, G.; Penny, W.; Brinker, J.; Marmur, J. D.; et al. (2002). Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation, 105, 1291-1297.
25. Grines, C. L.; Watkins, M. W.; Mahmarian, J. J.; Iskandrian, A. E.; Rade, J. J.; Marrott, P.; et al. (2003). A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol, 42, 1339-1347.
26. Grossman, P. M.; Han, Z.; Palasis, M.; Barry, J. J.; & Lederman, R. J. (2002). Incomplete retention after direct myocardial injection. Catheter Cardiovasc Interv, 55, 392-397.
27. Gyongyosi, M.; Khorsand, A.; Zamini, S.; Sperker, W.; Strehblow, C.; Kastrup, J.; et al. (2005). NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation, 112, I157-I165.
28. Hajjar, R. J.; Schmidt, U.; Matsui, T.; Guerrero, J. L.; Lee, K. H.; Gwathmey, J. K.; et al. (1998). Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci U S A, 95, 5251-5256.
29. Hayase, M.; Del Monte, F.; Kawase, Y.; Macneill, B. D.; McGregor, J.; Yoneyama, R.; et al. (2005). Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade. Am J Physiol Heart Circ Physiol, 288, H2995-H3000.
30. Hedman, M.; Hartikainen, J.; Syvanne, M.; Stjernvall, J.; Hedman, A.; Kivela, A.; et al. (2003). Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation, 107, 2677-2683.
31. Hedman, M.; Hartikainen, J.; & Yla-Herttuala, S. (2011). Progress and prospects: hurdles to cardiovascular gene therapy clinical trials. Gene Ther, 18, 743-749.
32. Henry, T. D.; Grines, C. L.; Watkins, M. W.; Dib, N.; Barbeau, G.; Moreadith, R.; et al. (2007). Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol, 50, 1038-1046.
33. Hoshino, K.; Kimura, T.; De Grand, A. M.; Yoneyama, R.; Kawase, Y.; Houser, S.; et al. (2006). Three catheter-based strategies for cardiac delivery of therapeutic gelatin microspheres. Gene Ther, 13, 1320-1327.
34. Hou, D.; Youssef, E. A.; Brinton, T. J.; Zhang, P.; Rogers, P.; Price, E. T.; et al. (2005). Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation, 112, I150-I156.
35. Ishikawa K, Ladage D, Tilemann L, Fish K, Kawase Y, Hajjar RJ (2011) Gene transfer for ischemic heart failure in a preclinical model. J Vis Exp
36. Ishikawa, K.; Tilemann, L.; Ladage, D.; Aguero, J.; Leonardson, L.; Fish, K.; et al. (2012). Cardiac gene therapy in large animals: bridge from bench to bedside. Gene Ther, 19, 670-677.
37. Jaski, B. E.; Jessup, M. L.; Mancini, D. M.; Cappola, T. P.; Pauly, D. F.; Greenberg, B.; et al. (2009). Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail, 15, 171-181.
38. 2+-ATPase in patients with advanced heart failure. Circulation, 124, 304-313.
39. Kastrup, J.; Jorgensen, E.; Fuchs, S.; Nikol, S.; Botker, H. E.; Gyongyosi, M.; et al. (2011). A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. EuroIntervention, 6, 813-818.
40. Kastrup, J.; Jorgensen, E.; Ruck, A.; Tagil, K.; Glogar, D.; Ruzyllo, W.; et al. (2005). Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris: a randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol, 45, 982-988.
41. Kaye, D. M.; Byrne, M. J.; & Power, J. M. (2010). Reply to Bridges. Gene Ther, 17, 565-566.
42. Kaye, D. M.; Preovolos, A.; Marshall, T.; Byrne, M.; Hoshijima, M.; Hajjar, R.; et al. (2007). Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol, 50, 253-260.
43. Kim JS, Hwang HY, Cho KR, Park EA, Lee W, Paeng JC, Lee DS, Kim HK, Sohn DW, Kim KB (2012) Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I clinical study. Gene Ther
44. Klugherz, B. D.; Song, C.; DeFelice, S.; Cui, X.; Lu, Z.; Connolly, J.; et al. (2002). Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus. Hum Gene Ther, 13, 443-454.
45. Kornowski, R.; Leon, M. B.; Fuchs, S.; Vodovotz, Y.; Flynn, M. A.; Gordon, D. A.; et al. (2000). Electromagnetic guidance for catheter-based transendocardial injection: a platform for intramyocardial angiogenesis therapy. Results in normal and ischemic porcine models. J Am Coll Cardiol, 35, 1031-1039.
46. Koruth, J. S.; Aryana, A.; Dukkipati, S. R.; Pak, H. N.; Kim, Y. H.; Sosa, E. A.; et al. (2011). Unusual complications of percutaneous epicardial access and epicardial mapping and ablation of cardiac arrhythmias. Circ Arrhythm Electrophysiol, 4, 882-888.
47. Kukula, K.; Chojnowska, L.; Dabrowski, M.; Witkowski, A.; Chmielak, Z.; Skwarek, M.; et al. (2011). Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD). Am Heart J, 161, 581-589.
48. Kutryk, M. J.; Foley, D. P.; van den Brand, M.; Hamburger, J. N.; van der Giessen, W. J.; deFeyter, P. J.; et al. (2002). Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol, 39, 281-287.
49. Laing, S. T.; & McPherson, D. D. (2009). Cardiovascular therapeutic uses of targeted ultrasound contrast agents. Cardiovasc Res, 83, 626-635.
50. Laitinen, M.; Hartikainen, J.; Hiltunen, M. O.; Eranen, J.; Kiviniemi, M.; Narvanen, O.; et al. (2000). Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther, 11, 263-270.
51. Lederman, R. J.; Guttman, M. A.; Peters, D. C.; Thompson, R. B.; Sorger, J. M.; Dick, A. J.; et al. (2002). Catheter-based endomyocardial injection with real-time magnetic resonance imaging. Circulation, 105, 1282-1284.
52. Li, J.; Li, G.; Huang, C.; Jiang, H.; Tang, Q.; Xu, J.; et al. (2002). Comparative study of catheter-mediated gene transfer into heart. Chin Med J (Engl), 115, 612-613.
53. Lin, H.; Parmacek, M. S.; Morle, G.; Bolling, S.; & Leiden, J. M. (1990). Expression of recombinant genes in myocardium in vivo after direct injection of DNA. Circulation, 82, 2217-2221.
54. Logeart, D.; Hatem, S. N.; Heimburger, M.; Le Roux, A.; Michel, J. B.; & Mercadier, J. J. (2001). How to optimize in vivo gene transfer to cardiac myocytes: mechanical or pharmacological procedures? Hum Gene Ther, 12, 1601-1610.
55. Losordo, D. W.; Vale, P. R.; Hendel, R. C.; Milliken, C. E.; Fortuin, F. D.; Cummings, N.; et al. (2002). Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation, 105, 2012-2018.
56. Losordo, D. W.; Vale, P. R.; Symes, J. F.; Dunnington, C. H.; Esakof, D. D.; Maysky, M.; et al. (1998). Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation, 98, 2800-2804.
57. Maurice, J. P.; Hata, J. A.; Shah, A. S.; White, D. C.; McDonald, P. H.; Dolber, P. C.; et al. (1999). Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. J Clin Invest, 104, 21-29.
58. Muhlhauser, J.; Jones, M.; Yamada, I.; Cirielli, C.; Lemarchand, P.; Gloe, T. R.; et al. (1996). Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors. Gene Ther, 3, 145-153.
59. Neubauer, S. (2007). The failing heart - an engine out of fuel. N Engl J Med, 356, 1140-1151.
60. Numaguchi, Y.; Okumura, K.; Harada, M.; Naruse, K.; Yamada, M.; Osanai, H.; et al. (2004). Catheter-based prostacyclin synthase gene transfer prevents in-stent restenosis in rabbit atheromatous arteries. Cardiovasc Res, 61, 177-185.
61. O'Donnell, J. M.; & Lewandowski, E. D. (2005). Efficient, cardiac-specific adenoviral gene transfer in rat heart by isolated retrograde perfusion in vivo. Gene Ther, 12, 958-964.
62. Otsuka, F.; Finn, A. V.; Yazdani, S. K.; Nakano, M.; Kolodgie, F. D.; & Virmani, R. (2012). The importance of the endothelium in atherothrombosis and coronary stenting. Nat Rev Cardiol, 9, 439-453.
63. Park, S. W.; Gwon, H. C.; Jeong, J. O.; Byun, J.; Kang, H. S.; You, J. R.; et al. (2001). Intracardiac echocardiographic guidance and monitoring during percutaneous endomyocardial gene injection in porcine heart. Hum Gene Ther, 12, 893-903.
64. Perlstein, I.; Connolly, J. M.; Cui, X.; Song, C.; Li, Q.; Jones, P. L.; et al. (2003). DNA delivery from an intravascular stent with a denatured collagen-polylactic-polyglycolic acid-controlled release coating: mechanisms of enhanced transfection. Gene Ther, 10, 1420-1428.
65. Raake, P.; von Degenfeld, G.; Hinkel, R.; Vachenauer, R.; Sandner, T.; Beller, S.; et al. (2004). Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery. J Am Coll Cardiol, 44, 1124-1129.
66. Ripa, R. S.; Wang, Y.; Jorgensen, E.; Johnsen, H. E.; Hesse, B.; & Kastrup, J. (2006). Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J, 27, 1785-1792.
67. Roques, C.; Salmon, A.; Fiszman, M. Y.; Fattal, E.; & Fromes, Y. (2007). Intrapericardial administration of novel DNA formulations based on thermosensitive Poloxamer 407 gel. Int J Pharm, 331, 220-223.
68. Rosengart, T. K.; Lee, L. Y.; Patel, S. R.; Sanborn, T. A.; Parikh, M.; Bergman, G. W.; et al. (1999). Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation, 100, 468-474.
69. Sanborn, T. A.; Hackett, N. R.; Lee, L. Y.; El-Sawy, T.; Blanco, I.; Tarazona, N.; et al. (2001). Percutaneous endocardial transfer and expression of genes to the myocardium utilizing fluoroscopic guidance. Catheter Cardiovasc Interv, 52, 260-266.
70. Sasano, T.; Kikuchi, K.; McDonald, A. D.; Lai, S.; & Donahue, J. K. (2007). Targeted high-efficiency, homogeneous myocardial gene transfer. J Mol Cell Cardiol, 42, 954-961.
71. Smits, P. C.; van Langenhove, G.; Schaar, M.; Reijs, A.; Bakker, W. H.; van der Giessen, W. J.; et al. (2002). Efficacy of percutaneous intramyocardial injections using a nonfluoroscopic 3-D mapping based catheter system. Cardiovasc Drugs Ther, 16, 527-533.
72. Stewart, D. J.; Hilton, J. D.; Arnold, J. M.; Gregoire, J.; Rivard, A.; Archer, S. L.; et al. (2006). Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther, 13, 1503-1511.
73. Stewart, D. J.; Kutryk, M. J.; Fitchett, D.; Freeman, M.; Camack, N.; Su, Y.; et al. (2009). VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther, 17, 1109-1115.
74. Sylven, C.; Sarkar, N.; Insulander, P.; Kenneback, G.; Blomberg, P.; Islam, K.; et al. (2002). Catheter-based transendocardial myocardial gene transfer. J Interv Cardiol, 15, 7-13.
75. Sylven, C.; Sarkar, N.; Ruck, A.; Drvota, V.; Hassan, S. Y.; Lind, B.; et al. (2001). Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris. Coron Artery Dis, 12, 239-243.
76. Symes, J. F.; Losordo, D. W.; Vale, P. R.; Lathi, K. G.; Esakof, D. D.; Mayskiy, M.; et al. (1999). Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg, 68, 830-836. discussion 836-837.
77. Tahlil, O.; Brami, M.; Feldman, L. J.; Branellec, D.; & Steg, P. G. (1997). The Dispatch catheter as a delivery tool for arterial gene transfer. Cardiovasc Res, 33, 181-187.
78. Thompson, C. A.; Nasseri, B. A.; Makower, J.; Houser, S.; McGarry, M.; Lamson, T.; et al. (2003). Percutaneous transvenous cellular cardiomyoplasty. A novel nonsurgical approach for myocardial cell transplantation. J Am Coll Cardiol, 41, 1964-1971.
79. Tilemann, L.; Ishikawa, K.; Weber, T.; & Hajjar, R. J. (2012). Gene therapy for heart failure. Circ Res, 110, 777-793.
80. Tse, H. F.; Xue, T.; Lau, C. P.; Siu, C. W.; Wang, K.; Zhang, Q. Y.; et al. (2006). Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN Channel reduces the dependence on electronic pacemaker in a sick-sinus syndrome model. Circulation, 114, 1000-1011.
81. Vale, P. R.; Losordo, D. W.; Milliken, C. E.; McDonald, M. C.; Gravelin, L. M.; Curry, C. M.; et al. (2001). Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation, 103, 2138-2143.
82. Vale, P. R.; Losordo, D. W.; Tkebuchava, T.; Chen, D.; Milliken, C. E.; & Isner, J. M. (1999). Catheter-based myocardial gene transfer utilizing nonfluoroscopic electromechanical left ventricular mapping. J Am Coll Cardiol, 34, 246-254.
83. Vandendriessche, T.; Thorrez, L.; Acosta-Sanchez, A.; Petrus, I.; Wang, L.; Ma, L.; et al. (2007). Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost, 5, 16-24.
84. Varenne, O.; Gerard, R. D.; Sinnaeve, P.; Gillijns, H.; Collen, D.; & Janssens, S. (1999). Percutaneous adenoviral gene transfer into porcine coronary arteries: is catheter-based gene delivery adapted to coronary circulation? Hum Gene Ther, 10, 1105-1115.
85. Vassalli, G.; Bueler, H.; Dudler, J.; von Segesser, L. K.; & Kappenberger, L. (2003). Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors. Int J Cardiol, 90, 229-238.
86. von der Leyen, H. E.; Mugge, A.; Hanefeld, C.; Hamm, C. W.; Rau, M.; Rupprecht, H. J.; et al. (2011). A prospective, single-blind, multicenter, dose escalation study of intracoronary iNOS lipoplex (CAR-MP583) gene therapy for the prevention of restenosis in patients with de novo or restenotic coronary artery lesion (REGENT I extension). Hum Gene Ther, 22, 951-958.
87. Wang, K.; Kessler, P. D.; Zhou, Z.; Penn, M. S.; Forudi, F.; Zhou, X.; et al. (2003). Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model. Mol Ther, 7, 597-603.
88. Wasala, N. B.; Shin, J. H.; & Duan, D. (2011). The evolution of heart gene delivery vectors. J Gene Med, 13, 557-565.
89. White, J. D.; Thesier, D. M.; Swain, J. B.; Katz, M. G.; Tomasulo, C.; Henderson, A.; et al. (2011). Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo. Gene Ther, 18, 546-552.
90. Wolff, J. A.; Malone, R. W.; Williams, P.; Chong, W.; Acsadi, G.; Jani, A.; et al. (1990). Direct gene transfer into mouse muscle in vivo. Science, 247, 1465-1468.
91. Yang, Z. J.; Zhang, Y. R.; Chen, B.; Zhang, S. L.; Jia, E. Z.; Wang, L. S.; et al. (2009). Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease. Mol Biol Rep, 36, 1323-1329.
92. Youssef, E. A.; Zhang, P.; Rogers, P. I.; Tremble, P.; Rokovich, J.; Johnstone, B. H.; et al. (2005). Enhancing myocardial plasmid expression by retrograde coronary venous delivery. Catheter Cardiovasc Interv, 65, 528-534.